ICT01 is a humanized, monoclonal antibody that activates γ9δ2 T cells, which are part of the innate immune system that is responsible for immunosurveillance for malignancy and infection, by targeting BTN3A (also known as CD277), a member of the butyrophilin superfamily of immuno-modulatory targets.
BTN3A is expressed on the surface of innate and adaptive immune cells (T cells, B cells and NK cells) and is overexpressed on a number of solid tumors (e.g., bladder, breast, colon, gastric, melanoma, ovarian and prostate) and hematologic cancers (e.g., leukemia & lymphoma). BTN3A appears essential for the activation of the anti-tumor immune response of γ9δ2 T cells.
ICT01 selectively activates circulating γ9δ2 T cells that leads to migration of γ9δ2 T cells out of the circulation and into target tissue (e.g., tumors or infection site). ICT01 has been shown to have anti-tumor activity against a range of cancers in in vitro and in vivo tumor models.